CORRECTION: Evolus Q4 EPS $(0.23) Misses $(0.15) Estimate, Sales $43.65M Miss $43.79M Estimate
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 30.3 percent increase over losses of $(0.33) per share from the same
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell
• Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Owlet (NYSE:OWLT) shares rose 43.8% to $0.49 during Monday’s after-market session. At the close, Owlet’s trading volume…
Needham Reiterates Buy on Evolus, Maintains $18 Price Target
Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $18 price target.
Evolus Not Affected By Recent Korean Court Ruling; Ruling By The Seoul Central District Court Does Not Affect Evolus’ Ability To Have Jeuveau Or Nuceiva Manufactured And Exported By Daewoong Or To Sell The Products In Any Of Its Markets
No Effect on Manufacture, Export, Supply or Sale of Jeuveau® or Nuceiva®
Settlement Agreement with Medytox Provided for Continued Manufacturing and Commercialization for Evolus Regardless of Any
Benzinga Pro’s Top 5 Stocks To Watch For Friday, January 27, 2023: AAPL, AMZN, COST, EOLS, AUVI
Apple (AAPL) - Will report quarterly results on Thursday of next week. Apple has historically reported at 4:30 p.m. ET. We'll discuss some analyst sentiment ahead of Apple's Q1 earnings
Evolus Receives Regulatory Approval For Nuceiva In Australia
Australia among the largest countries in the world for aesthetic neurotoxins1
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,
Here’s Why This Analyst Seems Highly Convinced With Evolus’ Outlook
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively.
Mizuho Maintains Buy on Evolus, Raises Price Target to $17
Mizuho analyst Uy Ear maintains Evolus (NASDAQ:EOLS) with a Buy and raises the price target from $15 to $17.